Currently, there are 380.96M common shares owned by the public and among those 360.35M shares have been available to trade.
The company’s stock has a 5-day price change of 1.07% and 8.37% over the past three months. HR shares are trading 4.41% year to date (YTD), with the 12-month market performance up to 7.60% higher. It has a 12-month low price of $12.77 and touched a high of $18.47 over the same period. HR has an average intraday trading volume of 3.55 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.81%, 2.66%, and 13.26% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Healthcare Realty Trust Inc (NYSE: HR) shares accounts for 113.53% of the company’s 380.96M shares outstanding.
It has a market capitalization of $6.53B and a beta (3y monthly) value of 0.86. The earnings-per-share (ttm) stands at -$1.51. The company has a debt-to-equity ratio at 0.93. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.07% over the week and 1.82% over the month.
Earnings per share for the fiscal year are expected to decrease by -67.04%, and 64.04% over the next financial year.
Looking at the support for the HR, a number of firms have released research notes about the stock. Wells Fargo stated their Underweight rating for the stock in a research note on July 30, 2024, with the firm’s price target at $17-$16. Wedbush coverage for the Healthcare Realty Trust Inc (HR) stock in a research note released on February 20, 2024 offered a Neutral rating with a price target of $15. Stifel was of a view on February 20, 2024 that the stock is Hold, while Deutsche Bank gave the stock Hold rating on January 30, 2024, issuing a price target of $18. BTIG Research on their part issued Buy rating on October 24, 2023.
